Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects
A Double-blind, Placebo-controlled, Randomized, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Oral Dose of MYMD1 Capsules in Healthy Male and Female Adult Subjects
Sponsor: TNF Pharmaceuticals, Inc.
Listed as NCT05077865, this PHASE1 trial focuses on Hashimoto Disease and remains completed. Sponsored by TNF Pharmaceuticals, Inc., it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — May 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Apr 2023 [monthly]
Completed PHASE1
First recorded
Apr 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TNF Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .